Ondrej Fiala1,2, Veronika Veskrnova3, Renata Chloupkova4, Alexandr Poprach5, Igor Kiss5, Katerina Kopeckova6, Ladislav Dusek4, Lubomir Slavicek7, Milan Kohoutek8, Jindrich Finek1, Marek Svoboda5, Lubos Petruzelka9, Ludmila Boubliková3, Josef Dvorak3, Bohuslav Melichar10, Tomas Buchler11. 1. Department of Oncology, University Hospital, Svobody 80, 304 60, Pilsen, Czech Republic. 2. Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Prague, Czech Republic. 3. Department of Oncology, First Faculty of Medicine, Charles University and Thomayer University Hospital, Videnska 800, 140 59, Prague, Czech Republic. 4. Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Netroufalky 5, 625 00, Brno, Czech Republic. 5. Department of Comprehensive Cancer Care and Faculty of Medicine, Masaryk Memorial Cancer Institute and Masaryk University, Zluty kopec 543/7, 656 53, Brno, Czech Republic. 6. Department of Oncology, Motol University Hospital and Second Faculty of Medicine, Charles University, V Uvalu 84, 150 00, Prague, Czech Republic. 7. Department of Oncology, Jihlava Hospital Comprehensive Cancer Centre, Jihlava, Czech Republic. 8. Department of Oncology, T Bata Hospital and Comprehensive Cancer Centre, Zlin, Czech Republic. 9. Department of Oncology, General University Hospital and Charles University First Faculty of Medicine, U Nemocnice 499/2, 128 08, Prague, Czech Republic. 10. Department of Oncology, Palacky University Medical School and Teaching Hospital, I.P. Pavlova 6, 775 20, Olomouc, Czech Republic. 11. Department of Oncology, First Faculty of Medicine, Charles University and Thomayer University Hospital, Videnska 800, 140 59, Prague, Czech Republic. tomas.buchler@ftn.cz.
Abstract
BACKGROUND: The addition of monoclonal antibodies targeting the epidermal growth factor receptor (anti-EGFR Abs) to chemotherapy for metastatic colorectal carcinoma (mCRC) is commonly delayed in the real-world clinical practice, usually because of late RAS testing results. OBJECTIVE: To determine whether delayed addition of anti-EGFR mAbs up to the fourth cycle of backbone chemotherapy adversely affected outcomes of mCRC patients treated with first-line regimens. PATIENTS AND METHODS: Clinical data of patients with histologically verified, RAS wild-type mCRC treated with first-line systemic therapy regimens containing anti-EGFR mAbs were retrospectively analysed from a national database. Patients were divided into three groups according to the timing of anti-EGFR mAbs addition to the chemotherapy backbone. Cohort A (n = 401) included patients in whom anti-EGFR mAbs were added to chemotherapy from the first cycle, cohort B (n = 71) patients with anti-EGFR mAbs added to chemotherapy from the second cycle, and cohort C (n = 101) patients who had anti-EGFR mAbs added to chemotherapy from the third or fourth cycle. RESULTS: Three hundred and thirty-six (58.6%) patients received panitumumab and 237 (41.4%) patients received cetuximab. The median progression-free survival (PFS) of the whole cohort was 12.2 months (95% confidence interval [CI] 10.9-13.5), and the median overall survival (OS) was 33.5 months (95% CI 27.6-39.4). The median PFS and OS for patients treated with anti-EGFR mAbs added to chemotherapy were 12.9 (95% CI 11.5-14.3) and 30.6 months (95% CI 25.2-36.1) for cohort A, 9.7 (95% CI 9.1-10.3) and not reached for cohort B, compared to 11.5 (95% CI 9.8-13.2) and 37.9 months (95% CI 28.6-47.3) for cohort C, respectively. CONCLUSIONS: Delayed addition of anti-EGFR mAbs to first-line chemotherapy was not associated with inferior survival or response rates.
BACKGROUND: The addition of monoclonal antibodies targeting the epidermal growth factor receptor (anti-EGFR Abs) to chemotherapy for metastatic colorectal carcinoma (mCRC) is commonly delayed in the real-world clinical practice, usually because of late RAS testing results. OBJECTIVE: To determine whether delayed addition of anti-EGFR mAbs up to the fourth cycle of backbone chemotherapy adversely affected outcomes of mCRC patients treated with first-line regimens. PATIENTS AND METHODS: Clinical data of patients with histologically verified, RAS wild-type mCRC treated with first-line systemic therapy regimens containing anti-EGFR mAbs were retrospectively analysed from a national database. Patients were divided into three groups according to the timing of anti-EGFR mAbs addition to the chemotherapy backbone. Cohort A (n = 401) included patients in whom anti-EGFR mAbs were added to chemotherapy from the first cycle, cohort B (n = 71) patients with anti-EGFR mAbs added to chemotherapy from the second cycle, and cohort C (n = 101) patients who had anti-EGFR mAbs added to chemotherapy from the third or fourth cycle. RESULTS: Three hundred and thirty-six (58.6%) patients received panitumumab and 237 (41.4%) patients received cetuximab. The median progression-free survival (PFS) of the whole cohort was 12.2 months (95% confidence interval [CI] 10.9-13.5), and the median overall survival (OS) was 33.5 months (95% CI 27.6-39.4). The median PFS and OS for patients treated with anti-EGFR mAbs added to chemotherapy were 12.9 (95% CI 11.5-14.3) and 30.6 months (95% CI 25.2-36.1) for cohort A, 9.7 (95% CI 9.1-10.3) and not reached for cohort B, compared to 11.5 (95% CI 9.8-13.2) and 37.9 months (95% CI 28.6-47.3) for cohort C, respectively. CONCLUSIONS: Delayed addition of anti-EGFR mAbs to first-line chemotherapy was not associated with inferior survival or response rates.
Authors: S Y Brulé; D J Jonker; C S Karapetis; C J O'Callaghan; M J Moore; R Wong; N C Tebbutt; Cr Underhill; D Yip; J R Zalcberg; D Tu; R A Goodwin Journal: Eur J Cancer Date: 2015-05-12 Impact factor: 9.162
Authors: Janja Ocvirk; Thomas Brodowicz; Fritz Wrba; Tudor E Ciuleanu; Galina Kurteva; Semir Beslija; Ivan Koza; Zsuzsanna Pápai; Diethelm Messinger; Ugur Yilmaz; Zsolt Faluhelyi; Suayib Yalcin; Demetris Papamichael; Miklós Wenczl; Zrinka Mrsic-Krmpotic; Einat Shacham-Shmueli; Damir Vrbanec; Regina Esser; Werner Scheithauer; Christoph C Zielinski Journal: World J Gastroenterol Date: 2010-07-07 Impact factor: 5.742
Authors: Julian Walter Holch; Ingrid Ricard; Sebastian Stintzing; Dominik Paul Modest; Volker Heinemann Journal: Eur J Cancer Date: 2016-11-29 Impact factor: 9.162
Authors: Eric Van Cutsem; Claus-Henning Köhne; István Láng; Gunnar Folprecht; Marek P Nowacki; Stefano Cascinu; Igor Shchepotin; Joan Maurel; David Cunningham; Sabine Tejpar; Michael Schlichting; Angela Zubel; Ilhan Celik; Philippe Rougier; Fortunato Ciardiello Journal: J Clin Oncol Date: 2011-04-18 Impact factor: 44.544
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Timothy S Maughan; Richard A Adams; Christopher G Smith; Angela M Meade; Matthew T Seymour; Richard H Wilson; Shelley Idziaszczyk; Rebecca Harris; David Fisher; Sarah L Kenny; Edward Kay; Jenna K Mitchell; Ayman Madi; Bharat Jasani; Michelle D James; John Bridgewater; M John Kennedy; Bart Claes; Diether Lambrechts; Richard Kaplan; Jeremy P Cheadle Journal: Lancet Date: 2011-06-05 Impact factor: 79.321
Authors: J C von Einem; V Heinemann; L Fischer von Weikersthal; U Vehling-Kaiser; M Stauch; H G Hass; T Decker; S Klein; S Held; A Jung; T Kirchner; M Haas; J Holch; M Michl; P Aubele; S Boeck; C Schulz; C Giessen; S Stintzing; D P Modest Journal: J Cancer Res Clin Oncol Date: 2014-05-10 Impact factor: 4.553
Authors: Tomas Buchler; Renata Chloupkova; Alexandr Poprach; Ondrej Fiala; Igor Kiss; Katerina Kopeckova; Ladislav Dusek; Veronika Veskrnova; Lubomir Slavicek; Milan Kohoutek; Jindrich Finek; Marek Svoboda; Lubos Petruzelka; Bohuslav Melichar Journal: Cancer Manag Res Date: 2018-12-28 Impact factor: 3.989
Authors: Lola-Jade Palmieri; Tomas Buchler; Antoine Meyer; Veronika Veskrnova; Ondrej Fiala; Petr Brabec; Jana Baranova; Romain Coriat Journal: Cancers (Basel) Date: 2022-03-10 Impact factor: 6.639